Ozathuia (Azathioprine)

Azathioprine, the active ingredient in Ozathuia, is an immunosuppressant presented as a tablet for oral use. It is used to prevent organ rejection and to manage certain autoimmune conditions in adults and children.

GNH USA supplies Ozathuia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Ozathuia is an immunosuppressive agent indicated for several disease pathways that involve abnormal immune activation. - Organ transplantation: helps maintain graft survival by suppressing immune‑mediated rejection. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Inflammatory bowel disease (Crohn’s disease and ulcerative colitis): assists in achieving and maintaining remission.

Adverse reactions to azathioprine can vary from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal discomfort that may improve with food. - Leukopenia: reduced white‑blood‑cell count, increasing infection risk. - Elevated liver enzymes: mild hepatic irritation detectable on routine labs. - Rash or mild skin irritation: occasional dermatologic response. - Fatigue: general sense of tiredness reported by some patients.

Serious or Rare Side Effects: - Pancytopenia: profound suppression of all blood cell lines, requiring immediate medical attention. - Severe hepatotoxicity: marked liver injury that may present with jaundice. - Opportunistic infections: including viral, fungal or bacterial infections due to immune suppression. - Malignancy risk: potential increased incidence of lymphomas and skin cancers with long‑term use. - Hypersensitivity reactions: such as Stevens‑Johnson syndrome or drug‑induced fever.

When prescribing azathioprine, clinicians should consider several safety measures to minimise risk. - Baseline testing: obtain complete blood count and liver function tests before initiation. - Monitoring: perform regular CBC and LFT assessments during treatment. - Infection vigilance: advise patients to report signs of infection promptly. - Pregnancy and lactation: use only if benefits outweigh risks; discuss with a specialist. - Drug-specific contraindications: avoid in patients with known hypersensitivity to azathioprine. - Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Azathioprine interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Allopurinol and febuxostat: may markedly increase azathioprine toxicity. - Antithymocyte globulin: additive immunosuppressive effect increasing infection risk.

Moderate Interactions (Monitor Closely): - Warfarin: azathioprine can enhance anticoagulant effect, requiring INR monitoring. - Mycophenolate mofetil: combined use may intensify bone‑marrow suppression. - Ribavirin: may increase risk of hematologic abnormalities. - Trimethoprim‑sulfamethoxazole: can potentiate myelosuppression, necessitating blood‑count checks.